aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results
Rhea-AI Summary
aTyr Pharma, Inc. (Nasdaq: LIFE) will report its first quarter 2020 financial results on May 12, 2020, after market close. The company is focused on developing innovative medicines targeting novel immunological pathways and is concentrating on its clinical-stage product candidate, ATYR1923, aimed at treating interstitial lung diseases. A conference call and webcast will follow the earnings report at 5:00 p.m. EDT, providing a platform for detailed discussions on the financial results and corporate updates.
AI-generated analysis. Not financial advice.
Positive
- Upcoming financial results announcement on May 12, 2020.
- Focus on innovative product candidate ATYR1923 targeting interstitial lung diseases.
Negative
- None.
News Market Reaction – LIFE
On the day this news was published, LIFE gained 1.39%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provide a corporate update after the market close on Tuesday, May 12, 2020.
Conference Call and Webcast Details:
Tuesday, May 12th @ 5:00 p.m. EDT / 2:00 p.m. PDT
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 1375605
Webcast: http://investors.atyrpharma.com/events-and-webcasts
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. For more information, please visit http://www.atyrpharma.com.
| Contact: | |
| Joyce Allaire | |
| Managing Director, LifeSci Advisors, LLC | |
| jallaire@lifesciadvisors.com | |